A Study of SHR-A1921 for Injection in Subjects With Advanced Solid Tumours

Summary

To assess the safety and tolerability of SHR-A1921 in patients with advanced solid tumours, to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and/or recommended phase II dose (RP2D) of SHR-A1921

Timeline

Start

2021-12-31

Primary completion

2024-08-31

Completion

2024-08-31

Drugs

Indications